# Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

> **NCT06674343** · PHASE3 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 144 (estimated)

## Conditions studied

- Advanced or Metastatic Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Furmonertinib

## Key facts

- **NCT ID:** NCT06674343
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06674343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06674343, "Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06674343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*